{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:26Z","timestamp":1793191766290,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":170,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.thromres.2025.109341","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:41:13Z","timestamp":1747309273000},"page":"109341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure"],"prefix":"10.1016","volume":"251","author":[{"given":"Hamdi","family":"Rezigue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Josset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.thromres.2025.109341_bb0005","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2025.109341_bb0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtha.2024.03.022","article-title":"Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A","volume":"22","author":"Josset","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109341_bb0015","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.thromres.2025.109341_bb0020","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.thromres.2025.109341_bb0025","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.thromres.2025.109341_bb0030","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2025.109341_bb0035","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic","volume":"22","author":"Lentz","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109341_bb0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2022.12.023","article-title":"The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation","volume":"21","author":"Bowyer","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2025.109341_bb0045","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtha.2023.03.007","article-title":"In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays","volume":"21","author":"Lund","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"5\u20136","key":"10.1016\/j.thromres.2025.109341_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"10.1016\/j.thromres.2025.109341_bb0055","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2025.109341_bb0060","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/bloodadvances.2023012285","article-title":"Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis","volume":"8","author":"Arcudi","year":"2024","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.thromres.2025.109341_bb0065","doi-asserted-by":"crossref","first-page":"E285","DOI":"10.1002\/ajh.27039","article-title":"Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: real-world retrospective multi-institutional cohort","volume":"98","author":"Batsuli","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.thromres.2025.109341_bb0070","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.thromres.2025.109341_bb0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12325-024-03032-3","article-title":"Efanesoctocog alfa versus standard and extended half-life factor VIII prophylaxis in adolescent and adult patients with haemophilia a without inhibitors","volume":"42","author":"Klamroth","year":"2025","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2025.109341_bb0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12325-024-03031-4","article-title":"Efanesoctocog alfa versus emicizumab in adolescent and adult patients with haemophilia a without inhibitors","volume":"42","author":"\u00c1lvarez Rom\u00e1n","year":"2024","journal-title":"Adv. Ther."},{"issue":"14","key":"10.1016\/j.thromres.2025.109341_bb0085","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109341_bb0090","unstructured":"Mancuso, ME. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study, \u2212 Late Breakthrough Session. ISTH 2024 Meeting."},{"issue":"3","key":"10.1016\/j.thromres.2025.109341_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"Wolberg","year":"2007","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2025.109341_bb0100","doi-asserted-by":"crossref","first-page":"24259","DOI":"10.1016\/S0021-9258(18)35759-4","article-title":"The effect of fibrin structure on fibrinolysis","volume":"267","author":"Gabriel","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2025.109341_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001721-199509000-00011","article-title":"Effect of fibrin structure on plasmin mediated dissolution of plasma clots","volume":"6","author":"Carr","year":"1995","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2025.109341_bb0110","article-title":"Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage","volume":"49","author":"Allen","year":"2002","journal-title":"Can. J. Anaesth."},{"issue":"1","key":"10.1016\/j.thromres.2025.109341_bb0115","doi-asserted-by":"crossref","first-page":"2222441","DOI":"10.1080\/19420862.2023.2222441","article-title":"Efficient production of bispecific antibody by FAST-Ig(TM) and its application to NXT007 for the treatment of hemophilia a","volume":"15","author":"Koga","year":"2023","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.thromres.2025.109341_bb0120","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109341_bb0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ijlh.14021","article-title":"The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement?","volume":"45","author":"Bowyer","year":"2023","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2025.109341_bb0130","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","author":"Hartmann","year":"2018","journal-title":"J. Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T09:58:40Z","timestamp":1768384720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"alternative-id":["S0049384825000908"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109341","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109341"}}